Breaking News

CTC, Recipharm Partner on Joint Phase I Services

June 23, 2014

Aims to provide more efficient Phase I studies

CTC (Clinical Trial Consultants) and Recipharm have entered into a collaboration to offer complete packages for Phase I studies including development and manufacture of clinical trial material. The partnership will also cover planning, performing and evaluation of the clinical trial.
 
Maria Lundberg, general manager Recipharm Pharmaceutical Development, said, “I am delighted about this collaboration. CTC has excellent experience in clinical trials and a unique Phase I unit at Uppsala University Hospital (Akademiska Sjukhuset). Together we will be able to offer customers faster and more cost-efficient Phase I studies. We can from now on take full responsibility for coordination of the work which might be valuable to small virtual companies.”
 
Bengt Dahlström, chief executive officer of CTC Clinical Trial said, “I am very pleased that CTC and Recipharm now can offer a joint service which will benefit from the companies longstanding expertise in contract development and manufacturing and early clinical research. This systematic integrated approach will help our clients to shorten project time-lines and at the same time obtain more information on the desirable properties of the drug formulation. Adaptive design is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol.”

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important